Important SOFT/TEXT subanalysis presented at #ESMOBreast24 by Otto Metzger showing a greater magnitude of AI vs Tamoxifen benefit in premenopausal patients with lobular histology

OncoAlert #bcsm

Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in pts with gBRCAm

Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER+ BC and gBRCAm?

@oncoalert #bcsm #ESMOBreast24

Data on retreatment with TDXd after grade 1 ILD from a pooled analysis presented by Hope Rugo demonstrates that 67% retreated without ILD recurrence

#ESMOBreast24 OncoAlert #bcsm

I am excited to present the BRIDGES study at #ESMObreast24 -showing the practice patterns and knowledge about IBC in low—and middle-income countries!

#globalonc #BCSM Dana-Farber IBC Program Tufts Medical Center ESMO - Eur. Oncology

Dario Trapani Filipa Lynce, MD, FASCO Sara Tolaney G Curigliano MD PhD Inas Abuali, MD Sarah Sewaralthahab, MD, MPH, ABIM

Does the use of assisted reproductive technologies by young BRCA carriers with breast cancer influence maternal prognosis or pregnancy outcomes?

Important and reassuring data presented by Matteo Lambertini, MD PhD at #ESMOBreast24 demonstrating the safety of ART

OncoAlert #bcsm

Countdown to #ESMOBreast2024 : Only 6 days left!

Excitement is building up as we gear up to attend this year's congress in Berlin, where key insights in the #BreastCancer domain await! Who else is joining us for there?

Find out more at: ow.ly/VeJn50RA95s

#MedEd #bcsm

Patient-level meta-analysis shows HER2DX is associated with survival outcomes in patients with early-stage HER2+ BC presented by Guillermo Villacampa

#ESMOBreast24 OncoAlert #bcsm

テロ起こすわ

Thanks to the #ESMOBreast24 conference organizers for allowing us to discuss important clinical trial design challenges in breast cancer ! ESMO - Eur. Oncology #bcsm Sara Tolaney Tatiana Prowell, MD Tomás Pascual Erika Hamilton, MD

Endorse. We desperately need this data but it is NOT ready for prime time decisions outside of trials!

#ESMOBreast24
#bcsm

Excited to have #TeamArvinas at #ESMOBreast24 , showcasing clinical data from our research collaboration with @Pfizer. Together, we're dedicated to innovating for patients in the fight against #BreastCancer . #BCSM

Very nice discussion by Thomas Bachelot

@oncalert #bcsm #ESMOBreast24

Hope Rugo presents data from CAPItello-291 on PFS2; most recv'd chemo as subsequent therapy; interestingly ~25% didn't get subsequent treatment in either arm

OncoAlert #ESMOBreast24 #bcsm

#ESMOBreast24
⭐️ Congratulations to Dr. ⁦Hope Rugo⁩ for being granted the ⁦ESMO - Eur. Oncology⁩ Breast Cancer Award 🥇 As amazing scientist, caregiver and human being she has a huge impact on the advances in the field and inspires countless colleagues #ESMOAmbassadors #bcsm

Rupert Bartsch delivers a sobering reminder:

Although we can DELAY brain mets 🧠 🦠 with better systemic therapy, if we look at trials we aren't really PREVENTING brain mets

#ESMOBreast24
#bcsm
ESMO - Eur. Oncology

The ADC + IO marriage is taking shape in the field of Breast Cancer. Rebecca Dent takes us through on the combination strategies of ADC+IO at the #ESMOBreast24 . #BCSM . Erika Hamilton, MD Matteo Lambertini, MD PhD ESMO - Eur. Oncology OncoAlert

Top 20 Breast Cancer Abstracts – #ASCO 2024

#bcsm #asco24

[Skeb]ありがとうございました！
テーマ：戦闘シーン　「剣から放たれる金属の輝き、制約を打ち砕く」

Dr Wolfgang Janni will lead this 🔑 trial asking of liquid biopsy improves survival as compared to usual follow up. An ambitious but critical question! #bcsm #ESMOBreast24

Emulated target trial looking at #statins in early #bcsm

Those that received statins had ⬆️ survival.

🎯 Question is what other healthy behaviors are associated with statin use?

Hard to conclude much with study design, MASTER randomized will help.

#ESMOBreast24
ESMO - Eur. Oncology